Data updated: Sep 20, 2026
Hypertrophic Cardiomyopathy Clinical Trial Landscape
Hypertrophic Cardiomyopathy is being studied across 58 clinical trials registered since 2008, with 25 programs currently active. The competitive pipeline includes 10 active Phase 3 trials, 8 active Phase 2 trials, and 0 active Phase 1 trials.
Top industry sponsors include Cytokinetics, Shandong Suncadia Medicine Co., Ltd., Bristol-Myers Squibb.
Trial activity
25 active / 58 total since 2008
Active by phase 10 Ph3 / 19 8 Ph2 / 21 0 Ph1 / 8 7 Ph4 / 10
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Cytokinetics 3 4 0
Shandong Suncadia Medicine Co., Ltd. 3 4 0
Bristol-Myers Squibb 1 2 0
Imbria Pharmaceuticals, Inc. 1 1 0
Bayer 1 0 0
Tenaya Therapeutics 1 0 0
Lexicon Pharmaceuticals 1 0 0
Edgewise Therapeutics, Inc. 1 0 0
Amckaus PTY LTD. 1 0 0
MyoKardia, Inc. 0 3 0
How the field has grown
New-trial starts peaked in 2025 (9 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (16 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 1
2017 1
2018 6
2019 2
2020 3
2021 4
2022 5
2023 5
2024 6
2025 9
2026 6
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (0) 0
2017 (0) 0
2018 (2) 283
2019 (1) 168
2020 (0) 0
2021 (1) 900
2022 (3) 250
2023 (3) 175
2024 (2) 283
2025 (3) 100
2026 (1) 532
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07023341 ACTIVE NOT RECRUITING
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bayer n=36
NCT06412666 ACTIVE NOT RECRUITING
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Cytokinetics n=65
NCT05182658 ACTIVE NOT RECRUITING
Empagliflozin in Hypertrophic Cardiomyopathy
National Institute of Cardiology, Warsaw, Poland n=250
NCT06481891 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals n=500
NCT06081894 ACTIVE NOT RECRUITING
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Cytokinetics n=500
NCT04848506 ENROLLING BY INVITATION
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Cytokinetics n=900
NCT07202897 RECRUITING
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Rennes University Hospital n=532
NCT07021976 ACTIVE NOT RECRUITING
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd. n=228
NCT06873828 NOT YET RECRUITING
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Yonsei University n=100
NCT07817186 NOT YET RECRUITING
Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT
Carelon Research n=25
NCT05186818 COMPLETED
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Cytokinetics n=282
NCT03723655 COMPLETED
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
Bristol-Myers Squibb n=314
NCT06116968 COMPLETED
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Corxel Pharmaceuticals n=40
NCT05767346 COMPLETED
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Cytokinetics n=175
NCT05174416 COMPLETED
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
LianBio LLC n=81
NCT05366101 COMPLETED
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
Newcastle-upon-Tyne Hospitals NHS Trust n=168
NCT03470545 COMPLETED
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. n=251
NCT02291237 TERMINATED
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Gilead Sciences n=172
NCT00821353 COMPLETED
Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
National Institute of Cardiology, Warsaw, Poland n=90
Related TheraRadar briefs
In-depth analysis connected to Hypertrophic Cardiomyopathy.
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only